Drug Toxicities in Second-Line Treatment of Chronic Myeloid Leukemia

被引：0
|
作者：
Datoguia, Tarcila S. [1 ]
Silva, Hugo R. C. [1 ]
Junior, Amauri M. C. R. [1 ]
Oliveira, Jose Salvador [1 ]
Conchon, Monika [1 ]
机构：
[1] Hosp Santa Marcelina, Hematol, Sao Paulo, Brazil
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Lichen planopilaris-like eruption in chronic myeloid leukemia patient during treatment with nilotinib as second-line therapy
    Gardellini, Angelo
    Guidotti, Francesca
    Zancanella, Michelle
    Maino, Elena
    Steffanoni, Sara
    Turrini, Mauro
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (04) : 969 - 971
  • [42] BUDGET IMPACT ANALYSIS OR PHARMACOLOGICAL THERAPY OF CHRONIC MYELOID LEUKEMIA (CML) WITH NILOTINIB AS THE SECOND-LINE TREATMENT IN RUSSIAN FEDERATION
    Serpik, V. G.
    Yagudina, R.
    VALUE IN HEALTH, 2015, 18 (07) : A442 - A442
  • [43] Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment Respond
    Landsman-Blumberg, Pamela B.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (11): : 1089 - 1089
  • [44] Bendamustine vs. fludarabine as second-line treatment in chronic lymphocytic leukemia
    Medgenberg, D.
    Balleisen, L.
    Heit, W.
    Knauf, W.
    Weiss, J.
    Freier, W.
    Eimermacher, H.
    Ibach, S.
    Niederle, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 563 - 563
  • [45] Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib
    Radich, Jerald P.
    Hochhaus, Andreas
    Giles, Francis J.
    Ross, David M.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Kim, Dong-Wook
    Fellague-Chebra, Rafik
    Sondhi, Manu
    Tiwari, Ranjan
    Mishra, Kaushal
    Mahon, Francois-Xavier
    BLOOD, 2019, 134
  • [46] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Maino, E.
    Calistri, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Medeot, M.
    Ambrosetti, A.
    Semenzato, G.
    Fanin, R.
    HAEMATOLOGICA, 2015, 100 : 132 - 132
  • [47] BUDGET IMPACT ANALYSIS FOR THE FIRST-LINE AND SECOND-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Lachaine, J.
    Kouroukis, C. T.
    VALUE IN HEALTH, 2016, 19 (03) : A244 - A245
  • [48] Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia
    Toptas, Tayfur
    Demirtas, Derya
    Yanik, Ahmet Mert
    Candan, Ozlem
    Arikan, Fatma
    Salim, Secil
    Menguc, Meral
    Yilmaz, Asu Fergun
    Tuglular, Tulin
    Kaygusuz Atagunduz, Isik
    HEMATOLOGY, 2025, 30 (01)
  • [49] Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?
    Brown, Jennifer R.
    HAEMATOLOGICA, 2018, 103 (07) : 1096 - 1098
  • [50] Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA)
    Breccia, Massimo
    Olimpieri, Pier Paolo
    Celant, Simone
    Olimpieri, Odoardo Maria
    Pane, Fabrizio
    Iurlo, Alessandra
    Summa, Valentina
    Corradini, Paolo
    Russo, Pierluigi
    ANNALS OF HEMATOLOGY, 2023, 102 (05) : 1257 - 1259
12345